Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
about
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathwayGaleterone for the treatment of advanced prostate cancer: the evidence to dateA sting in the tail: the N-terminal domain of the androgen receptor as a drug targetTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerCancer wars: natural products strike backAbiraterone in the treatment of metastatic castration-resistant prostate cancerTargeting the adaptive molecular landscape of castration-resistant prostate cancerEmerging data on androgen receptor splice variants in prostate cancerCYP17 inhibitors for prostate cancer therapyClassification of drug molecules considering their IC50 values using mixed-integer linear programming based hyper-boxes method.Androgen receptor splice variants and prostate cancer: From bench to bedside.Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy.17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directionsCYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Novel drugs targeting the androgen receptor pathway in prostate cancer.CYP17A1 inhibitors in castration-resistant prostate cancerThe hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Catalytically relevant electrostatic interactions of cytochrome P450c17 (CYP17A1) and cytochrome b5.Benign prostatic hyperplasia: An overview of existing treatment.The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerNew hormonal therapies for castration-resistant prostate cancer.Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerTargeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.Emerging targeted therapies for castration-resistant prostate cancer.First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular DynamicsGaleterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.The changing landscape in the treatment of metastatic castration-resistant prostate cancer.The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
P2860
Q24603649-AC7A21BA-4ABA-40D6-9B21-20E917DEE325Q26739887-53407EE4-0D9B-4964-B57F-CCEC2A564FCDQ26747094-807585F6-A60E-4CF3-8765-8559FA3B1AD8Q26750620-2375F1C1-5F83-4755-8B47-BB7D2D8F30F2Q26850074-3A43255D-F384-439D-9556-B00EAA3802E3Q26853635-8E01705D-98FD-4012-BFBA-00F90EA2E0D1Q27022821-952A71FF-146F-4744-86FC-123C0D6A71E0Q28077830-BAF6157A-DC85-4B05-BE45-D9254BDC11C5Q28298818-2155AF26-FC98-41A6-B726-8BC139F90E81Q33373829-357653D3-7D81-4691-9034-3E804622621CQ33567024-4CEA3F1F-D2FB-4888-9B93-87A81B07C600Q33590201-9FFA0B83-E055-4B7F-B5E3-161479714944Q33621403-0563792D-69CE-4AB1-9AE5-8E2445F62D45Q33623428-C93F735E-A868-46F2-91C5-0A65B928F6E4Q33696276-0C9B0F5D-2750-4F88-88A7-D94E5F750354Q33754817-96F4107C-85FB-42C1-B162-77C2F0289533Q33821586-66627B61-951F-4A4C-8AFB-7A68FDA7FEF8Q34250227-39BFBB65-561A-4119-9A16-5616034EBB41Q34291736-344D7EE0-82C6-458B-A804-912228B2D204Q34324736-B7F292EA-02E3-40D5-99D8-E628959DB5D1Q34387852-F37135E0-217A-42A9-A3DB-4F02726F4585Q34395777-4B19BFDB-348F-4FC8-BA4F-20DACD6B9E15Q34456638-D38B09A7-9FEE-4393-8BE6-A91BE60F4BCDQ34525556-CB2DC256-193B-408B-9032-D7A59C4B80D6Q34604646-C02F7AD2-ACBC-4A3D-83E7-FB2E23DF06BAQ34619574-FCBB31B7-401D-4C66-AD15-B40F7E794D71Q34634130-F55A7FAC-FDA8-4651-ABA0-2974546C1B63Q34706497-84A54A96-B16D-4EDC-B3C7-6D51B5E8C743Q34956110-F7C458B4-BCB4-4E9A-997A-E2BDC4DB3D5FQ35196715-7CB1074D-7BC1-4A43-85F7-9BC38A1D0F24Q35209369-1189A5D3-20EB-4C35-9F71-3B041391E78BQ35210730-916A6CF6-6FDA-4A5E-842F-5B8B725DCE9EQ35962274-4FBCFE7E-14A5-464B-ACF5-20D0116FE4C1Q35999255-43ADAE72-D90D-4F53-A5DB-5F6CBBA07C79Q36117828-9394917C-9BEE-4B7C-9CF4-45B5775700E4Q36297428-344FA6DC-4EDA-40E4-929C-FA2DD09C931AQ36413805-79AE1E8A-A1A9-4331-8417-A6C72515E6C2Q36515526-74B56886-BCE7-460B-AF0D-B6ABFA0A21D9Q36880048-394C1BF8-2F51-431D-9988-1DCFC9AEF4B7Q37098796-27A33ACC-3C1E-4CCA-8B1A-8E237E6F509A
P2860
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Novel C-17-heteroaryl steroida ...... ostate cancer xenograft model.
@en
type
label
Novel C-17-heteroaryl steroida ...... ostate cancer xenograft model.
@en
prefLabel
Novel C-17-heteroaryl steroida ...... ostate cancer xenograft model.
@en
P2093
P356
P1476
Novel C-17-heteroaryl steroida ...... ostate cancer xenograft model.
@en
P2093
Angela M H Brodie
Donnell Newman
Lalji K Gediya
Pankaj Chopra
Rena Farquhar
Ritesh Kataria
Tadas S Vasaitis
Venkatesh D Handratta
Vincent C O Njar
P304
P356
10.1021/JM040202W
P407
P577
2005-04-01T00:00:00Z